| Property | Value |
|---|
|
?:abstract
|
-
Pneumonia of unknown cause detected in Wuhan, China was first reported to the WHO Country Office in China on 31 December 2019 The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020 Currently, there is no Vaccine against COVID-19 pandemic and infection is spreading worldwide vary rapidly there is an exigent requirement of practicable drug treatment Drug repurposing is one of the most promising approaches for that Many reports are available with in silico drug repurposing but the majority of them engrossed on a single target The present study aimed at screening the approved against Covid19 protein and extract the combination of operational comprehensively A total of 1735 drug molecules against all COVID19 protein structures and sequential screening recognize the better potential of anti-HCV drugs over anti-HIV drugs The study designated Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine Ergotamin as promising drug candidates for covid19 treatment The computational analysis also reveled the better potential of proposed drugs over the currently used drug combination for COVID19 drugs
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Drug Repurposing of Approved Drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for Combating COVID19
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}